KalVista Pharmaceuticals (KALV) Competitors $10.61 +0.34 (+3.31%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KALV vs. ALIM, ABUS, BYSI, MGTA, BCRX, HRMY, GMTX, KNSA, RXRX, and GLPGShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Alimera Sciences (ALIM), Arbutus Biopharma (ABUS), BeyondSpring (BYSI), Magenta Therapeutics (MGTA), BioCryst Pharmaceuticals (BCRX), Harmony Biosciences (HRMY), Gemini Therapeutics (GMTX), Kiniksa Pharmaceuticals (KNSA), Recursion Pharmaceuticals (RXRX), and Galapagos (GLPG). These companies are all part of the "medical" sector. KalVista Pharmaceuticals vs. Alimera Sciences Arbutus Biopharma BeyondSpring Magenta Therapeutics BioCryst Pharmaceuticals Harmony Biosciences Gemini Therapeutics Kiniksa Pharmaceuticals Recursion Pharmaceuticals Galapagos Alimera Sciences (NASDAQ:ALIM) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Do analysts rate ALIM or KALV? Alimera Sciences currently has a consensus target price of $8.00, suggesting a potential upside of 44.40%. KalVista Pharmaceuticals has a consensus target price of $26.00, suggesting a potential upside of 145.05%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Alimera Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alimera Sciences 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ALIM or KALV more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Alimera Sciences' net margin of -14.74%. Alimera Sciences' return on equity of -33.70% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alimera Sciences-14.74% -33.70% -9.63% KalVista Pharmaceuticals N/A -97.37%-82.39% Which has more volatility & risk, ALIM or KALV? Alimera Sciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Does the MarketBeat Community favor ALIM or KALV? Alimera Sciences received 19 more outperform votes than KalVista Pharmaceuticals when rated by MarketBeat users. However, 74.39% of users gave KalVista Pharmaceuticals an outperform vote while only 55.97% of users gave Alimera Sciences an outperform vote. CompanyUnderperformOutperformAlimera SciencesOutperform Votes35655.97% Underperform Votes28044.03% KalVista PharmaceuticalsOutperform Votes33774.39% Underperform Votes11625.61% Do institutionals and insiders believe in ALIM or KALV? 99.8% of Alimera Sciences shares are owned by institutional investors. 31.4% of Alimera Sciences shares are owned by company insiders. Comparatively, 10.5% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better valuation and earnings, ALIM or KALV? Alimera Sciences has higher revenue and earnings than KalVista Pharmaceuticals. Alimera Sciences is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlimera Sciences$99.68M2.91-$20.13M-$1.57-3.53KalVista PharmaceuticalsN/AN/A-$126.64M-$3.53-3.01 Does the media refer more to ALIM or KALV? In the previous week, KalVista Pharmaceuticals had 1 more articles in the media than Alimera Sciences. MarketBeat recorded 1 mentions for KalVista Pharmaceuticals and 0 mentions for Alimera Sciences. Alimera Sciences' average media sentiment score of 0.00 equaled KalVista Pharmaceuticals'average media sentiment score. Company Overall Sentiment Alimera Sciences Neutral KalVista Pharmaceuticals Neutral SummaryAlimera Sciences beats KalVista Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Ad Timothy SykesHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$458.51M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-3.019.74115.4815.20Price / SalesN/A381.431,483.2092.69Price / CashN/A47.3339.6534.06Price / Book2.185.324.665.02Net Income-$126.64M$153.56M$119.06M$225.46M7 Day Performance-9.16%0.12%0.80%0.37%1 Month Performance-10.39%15.23%5.66%3.57%1 Year Performance22.45%41.16%36.76%29.43% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals3.3891 of 5 stars$10.61+3.3%$26.00+145.1%+21.0%$458.51MN/A-3.01150ALIMAlimera SciencesN/A$5.54flat$8.00+44.4%N/A$290.24M$99.68M-3.53150Analyst ForecastABUSArbutus Biopharma2.2958 of 5 stars$4.05+2.0%$5.25+29.6%+115.2%$749.21M$10.06M-9.0073Upcoming EarningsBYSIBeyondSpringN/A$2.20-2.7%N/A+120.4%$85.86M$1.88M0.0080Positive NewsMGTAMagenta TherapeuticsN/A$0.70-7.7%N/A+0.0%$42.44MN/A0.0067Gap DownBCRXBioCryst Pharmaceuticals3.9428 of 5 stars$8.15+2.5%$14.17+73.8%+47.1%$1.68B$382.24M-11.16530Upcoming EarningsHRMYHarmony Biosciences4.9032 of 5 stars$35.75+3.6%$44.38+24.1%+34.9%$2.03B$582.02M18.33200Earnings ReportAnalyst ForecastInsider SellingShort Interest ↓Analyst RevisionNews CoverageGMTXGemini TherapeuticsN/A$46.19+0.4%N/A+2.9%$2.00BN/A-46.1930KNSAKiniksa Pharmaceuticals2.6664 of 5 stars$27.59+0.5%$33.60+21.8%+48.4%$1.96B$338.93M-172.43220Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRXRXRecursion Pharmaceuticals2.9187 of 5 stars$6.87+6.0%$9.40+36.8%+25.7%$1.93B$44.58M-4.24400Upcoming EarningsGLPGGalapagos0.5723 of 5 stars$28.76-0.7%$31.00+7.8%-19.3%$1.90B$261.40M0.001,123Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies ALIM Alternatives ABUS Alternatives BYSI Alternatives MGTA Alternatives BCRX Alternatives HRMY Alternatives GMTX Alternatives KNSA Alternatives RXRX Alternatives GLPG Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KALV) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
